Drugs / Budesonide and Formoterol Fumarate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07525375 Background | Apr 2026 → May 2029 expected | asthma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Budesonide and Formoterol Fumarate | “A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) Versus Placebo in Participants of 4 to...” NCT07525375 ↗ |
| Known as | BFF | “A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) Versus Placebo in Participants of 4 to...” NCT07525375 ↗ |
| Route | Inhaled | “BFF MDI will be administered via oral inhalation BID.” NCT07525375 ↗ |